EWEleanor M. Walker

Eleanor M. Walker

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eleanor M. Walker has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increasing Prostate Cancer Education and Screening for Black Men in Southeastern Michigan: Your Prostate, Your Health

    by Shane A. Tinsley, Doreen Dankerlui, Camille Romain, Wilma Ruffin, Eric Brown, Clarence Burnett, Donna Long, Karen Yacobucci, Jaye Clement, Abisola Fasakin, et al.

    Black Men (BM) have disproportionately higher mortality rates from prostate cancer (PCa) and present with more advanced disease. Early screening may improve outcomes. The aim of our project was to provide education, screening, and provider outreach with a long-term goal to decrease the disproportionate number of PCa deaths in BM. We conducted focus group discussions with BM to assess their perceptions and understanding of PCa and screening. Focus groups aided in the development of educational materials. Educational materials were distributed at community events. Screening was offered, at select events, using prostate-specific antigen (PSA) testing. Men with PSA levels of ≥ 4 ng/ml were contacted for follow-up. The project included training for Henry Ford Health (HFH) providers and an assessment of their PCa screening practice. We completed 4 focus groups and distributed ~ 1000 PCa educational brochures. We participated in 45 community events between March 2022 to June 30, 2023. 340 men were screened. 28 men had an elevated PSA, and 17 men did not complete follow-up. Multiple HFH provider educational sessions were conducted. Of 129 providers who completed a screening practice assessment, 78 (60%) routinely offered PSA screening to men between ages 55–69. Between 2018 to 2023 at HFH, the PSA screening rate overall increased from 8.2% to 12.7%. Although our outreach efforts were effective at increasing PSA screening, 60.7% of men screened in our community events with elevated PSA did not follow-up. Future efforts should further reduce barriers to PCa screening and follow-up.


  • Open Access

    Factors associated with breast lymphedema after adjuvant radiation therapy in women undergoing breast conservation therapy

    by Summer Sami Yono, Cara Cannella, Madeleine Gonte, Sanjay Rama, Simeng Zhu, Jenna Luker, Maristella S. Evangelista, Jessica Bensenhaver, Eleanor M. Walker, Dunya Atisha


  • Open Access

    BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy

    by Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, Stephen L. Brown, Benjamin Movsas, Eleanor Walker, Shyam Nyati

    BUB1 is overexpressed in most human solid cancers, including breast cancer. Higher BUB1 levels are associated with a poor prognosis, especially in patients with triple-negative breast cancer (TNBC). Women with TNBC often develop resistance to chemotherapy and radiotherapy, which are still the mainstay of treatment for TNBC. Our previous studies demonstrated that a BUB1 kinase inhibitor (BAY1816032) reduced tumor cell proliferation and significantly enhanced radiotherapy efficacy in TNBC. In this study, we evaluated the effectiveness of BAY1816032 with a PARP inhibitor (olaparib), platinum agent (cisplatin), and microtubule poison (paclitaxel) alone or in combination with radiotherapy using cytotoxicity and clonogenic survival assays. BUB1 inhibitors sensitized BRCA1/2 wild-type SUM159 and MDA-MB-231 cells to olaparib, cisplatin, and paclitaxel synergistically (combination index; CI < 1). BAY1816032 significantly increased the radiation sensitization of SUM159 and MDA-MB-231 by olaparib, cisplatin, or paclitaxel at non-toxic concentrations (doses well below the IC50 concentrations). Importantly, the small molecular inhibitor of BUB1 synergistically (CI < 1) sensitized the BRCA mutant TNBC cell line HCC1937 to olaparib. Furthermore, the BUB1 inhibitor significantly increased the radiation enhancement ratio (rER) in HCC1937 cells (rER 1.34) compared to either agent alone (BUB1i rER 1.19; PARPi rER 1.04). The data presented here are significant as they provide proof that inhibition of BUB1 kinase activity sensitizes TNBC cell lines to a PARP inhibitor and radiation, irrespective of BRCA1/2 mutation status. Due to the ability of the BUB1 inhibitor to sensitize TNBC to different classes of drugs (platinum, PARPi, microtubule depolarization inhibitors), this work strongly supports the role of BUB1 as a novel molecular target to improve chemoradiation efficacy in TNBC and provides a rationale for the clinical evaluation of BAY1816032 as a chemosensitizer and chemoradiosensitizer in TNBC.


  • Open Access

    BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy

    by Sushmitha Sriramulu, Shivani Thoidingjam, Farzan Siddiqui, Stephen L Brown, Benjamin Movsas, Eleanor Walker, Shyam Nyati

    BUB1 is overexpressed in most human solid cancers including breast cancer. Higher BUB1 levels are associated with poor prognosis especially in patients with triple-negative breast cancer (TNBC). Women with TNBC often develop resistance to chemotherapy and radiotherapy, which are still the mainstay of treatment for TNBC. Our previous studies demonstrated that BUB1 kinase inhibitor (BAY1816032) reduced tumor cell proliferation and significantly enhanced radiotherapy efficacy in TNBC. In this study, we evaluated the effectiveness of BAY1816032 with a PARP inhibitor (olaparib), platinum agent (cisplatin), and microtubule poison (paclitaxel) alone or in combination with radiotherapy using cytotoxicity and clonogenic survival assays. BUB1 inhibitor sensitized BRCA1/2 wild-type SUM159 and MDA-MB-231 cells to olaparib, cisplatin and paclitaxel synergistically (combination index; CI


  • Open Access

    Abstract C130: Increasing prostate cancer education and screening for black men in southeastern Michigan: Your prostate, your health

    by Shane A. Tinsley, Doreen Dankerlui, Camille Romain, Wilma Ruffin, Eric Brown, Clarence Burnett, Donna Long, Karen Yacobucci, Jaye Clement, Abisola Fasakin, et al.

    Background   Black Men (BM) have disproportionately higher mortality rates from prostate cancer (PCa) and present with more advanced disease. Early screening may improve outcomes. The aim of our project was to provide education, screening, and provider outreach in efforts to decrease the disproportionate number of PCa deaths in Black men. Methods   We conducted focus group discussions with BM to assess their perceptions and understanding of PCa and screening. Focus groups aided in the development of educational materials. Educational materials were distributed at community events. Attendants were asked to participate in a survey to assess their knowledge, interest, and perceptions of prostate cancer screening and diagnosis. Screening was offered, at select events, using prostate-specific antigen (PSA) testing. Men with PSA levels of ≥4 ng/ml were contacted for follow-up. The project included training for Henry Ford Health (HFH) providers and an assessment of their PCa screening practice. Results   We completed 4 focus groups and distributed ~1000 PCa educational brochures. To date, 136 men completed the survey. The least common response (n=33, 21.17%) to signs and symptoms associated with prostate cancer was “Prostate cancer can have no symptoms.” while the most common response (n=108, 66.42%) stated that prostate cancer is associated with “Having a hard time passing urine.” The most common response (n=106, 79.1%) to the perceived barrier to prostate cancer screening was “Lack of education around the importance of screening.” Furthermore, when participants were asked why men do not get prostate cancer screening the most common response (n=119, 79.33%) was “Fear of diagnosis.” The greatest number of survey responses (n=90, 69.77%) stated that “Social Media” is how they learned about prostate cancer screening. The largest number of responses (n=83, 57.24%) for the preferred method of communication regarding getting a prostate cancer screening was, “Text message reminder to schedule an appointment.” We participated in 42 community events between March 2022 to May 2023. 323 men were screened. 27 men had an elevated PSA, and 14 of these men did not complete follow-up. The reasons for the lack of follow-up were inability to re-contact (n=10, 71%), lack of insurance (n=2, 14%), no show to appointment (n=1, 7%), fear (n=1, 7%), and unknown (n=1, 7%). HFH provider educational sessions were conducted. Of 129 providers who completed a screening practice assessment, 78 (60%) routinely offered PSA screening to men between ages 55-69. Between 2018 to 2023 at HFH, the PSA screening rate overall increased from 8.2% to 12.7%. Conclusion   Although our outreach efforts were effective at increasing PSA screening, half the men with elevated PSA did not follow-up. Future efforts should further reduce barriers to PCa screening and follow-up. Citation Format: Shane A. Tinsley, Doreen Dankerlui, Camille Romain, Wilma Ruffin, Clarence Burnett, Donna Long, Karen Yacobucci, Jaye Clement, Abisola Fasakin, Biola Makinde-Odusola, Eric Williams, Tiffany Fields, Firas Abdollah, Daniel Moore, Clara Hwang, Eleanor M. Walker. Increasing prostate cancer education and screening for black men in southeastern Michigan: Your prostate, your health [abstract]. In: Proceedings of the 16th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2023 Sep 29-Oct 2;Orlando, FL. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2023;32(12 Suppl):Abstract nr C130.

  • Open Access

    OGBN O02 Ergonomics in laparoscopic cholecystectomy. Do we need to change our practice to look after ourselves?

    by Matt Browning, Courtney Johnson, Megan Gore, Anuradha Alwis, Wunna Soe, Eleanor Walker, James Walmsley, David Chan

    Background: Up to 80% of surgeons report musculoskeletal problems which significantly affect their personal and professional lives. The cost of back pain alone in the NHS costs £400 million per year (for all staff), and surveyed surgeons report 40% have sustained an injury at work. Laparoscopic cholecystectomy is one of the most frequently performed surgical procedures but the musculoskeletal impact of this procedure on surgeons is unknown, though anecdotally it is likely to be high. Methods: We observed the positions held by surgeons undertaking laparoscopic cholecystectomy and measured them against the Rapid Entire Body Assessment (REBA) score, which is widely used to assess the risk of an activity causing musculoskeletal injury. The higher the score, the less ergonomic the posture and the higher the risk of long term harm. Photographs were taken of the operating surgeon with consent (excluding views of the patient) and then measured against the score to assess the risk. Operations were graded to give an average risk score which represents the need for a change of process to safeguard staff. Results: Eight laparoscopic cholecystectomies, undertaken by 6 different surgeons were analysed. Scores for trunk posture were generally low but score for upper limb position were higher. The mean and median REBA scores were both 4 and the maximum score during one operation was 6. Conclusions: The scores measured in this small study were very consistent and suggest that the practice of laparoscopic cholecystectomy as currently practised has a medium risk of causing operator harm; practice change is recommended to safeguard staff. Further research is needed with larger sample sizes as well as different arms for techniques such as position changes or robotic surgery, while observing outcomes for patients and time taken.

  • Advancing Health Equity, Inclusion, and Belonging in Integrative Oncology

    by Ana María López, Leigh Leibel, Doreen Stein-Seroussi, Carolina Salvador, Rebecca Leary Safon, Tanya T.J. Riggs, Melvin D. Mann, Jodi MacLeod, Eleanor M. Walker

    Journal of Integrative and Complementary Medicine

  • Open Access

    Integrative Oncology Education: An Emerging Competency for Oncology Providers

    by Safiya Karim, Rita Benn, Linda E. Carlson, Judith Fouladbakhsh, Heather Greenlee, Rick Harris, N. Lynn Henry, Shruti Jolly, Sabrina Mayhew, Lisa Spratke, et al.

    A growing number of cancer patients use complementary and alternative therapies during and after conventional cancer treatment. Patients are often reluctant to discuss these therapies with their oncologist, and oncologists may have limited knowledge and confidence on how to advise patients on the appropriate use. Integrative oncology is a patient-centered, evidence-informed field that utilizes mind–body practices, lifestyle modifications and/or natural products interwoven with conventional cancer treatment. It prioritizes safety and best available evidence to offer appropriate interventions alongside conventional care. There are few opportunities for oncologists to learn about integrative oncology. In this commentary, we highlight the Integrative Oncology Scholars (IOS) program as a means to increase competency in this growing field. We provide an overview of several integrative oncology modalities that are taught through this program, including lifestyle modifications, physical activity, and mind–body interventions. We conclude that as more evidence is generated in this field, it will be essential that oncology healthcare providers are aware of the prevalent use of these modalities by their patients and cancer centers include Integrative Oncology trained physicians and other healthcare professionals in their team to discuss and recommend evidence-based integrative oncology therapies alongside conventional cancer treatments to their patients.


  • Open Access

    Evaluating organ delineation, dose calculation and daily localization in an open-MRI simulation workflow for prostate cancer patients

    by Anthony Doemer, Indrin J Chetty, Carri Glide-Hurst, Teamour Nurushev, David Hearshen, Milan Pantelic, Melanie Traughber, Joshua Kim, Kenneth Levin, Mohamed A Elshaikh, et al.

    This study describes initial testing and evaluation of a vertical-field open Magnetic Resonance Imaging (MRI) scanner for the purpose of simulation in radiation therapy for prostate cancer. We have evaluated the clinical workflow of using open MRI as a sole modality for simulation and planning. Relevant results related to MRI alignment (vs. CT) reference dataset with Cone-Beam CT (CBCT) for daily localization are presented. Ten patients participated in an IRB approved study utilizing MRI along with CT simulation with the intent of evaluating the MRI-simulation process. Differences in prostate gland volume, seminal vesicles, and penile bulb were assessed with MRI and compared to CT. To evaluate dose calculation accuracy, bulk-density-assignments were mapped onto respective MRI datasets and treated IMRT plans were re-calculated. For image localization purposes, 400 CBCTs were re-evaluated with MRI as the reference dataset and daily shifts compared against CBCT-to-CT registration. Planning margins based on MRI/CBCT shifts were computed using the van Herk formalism. Significant organ contour differences were noted between MRI and CT. Prostate volumes were on average 39.7% (p = 0.002) larger on CT than MRI. No significant difference was found in seminal vesicle volumes (p = 0.454). Penile bulb volumes were 61.1% higher on CT, without statistical significance (p = 0.074). MRI-based dose calculations with assigned bulk densities produced agreement within 1% with heterogeneity corrected CT calculations. The differences in shift positions for the cohort between CBCT-to-CT registration and CBCT-to-MRI registration are −0.15 ± 0.25 cm (anterior-posterior), 0.05 ± 0.19 cm (superior-inferior), and −0.01 ± 0.14 cm (left-right). This study confirms the potential of using an open-field MRI scanner as primary imaging modality for prostate cancer treatment planning simulation, dose calculations and daily image localization.